Saffron Sleep Latency Meta-analysis: What the Evidence Says

Quick Answer

Saffron Sleep Latency Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Despite the availability of conventional treatments for mental disorders, such as antidepressants, anxiolytics, and antipsychotics, these options are often associated with various side effects that can impact patients' quality of life and adherence to treatment. [Dormal Valérie (2025); evidence level 2]
• Additionally, the use of conventional antidepressant drugs, like selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), is often characterized by incomplete therapeutic response, limited remission rates, high risk of relapse, poor tolerability, and frequent early discontinuation, highlighting the need for alternative or adjunctive therapeutic options with fewer negative consequences. [Dormal Valérie (2025); evidence level 2]
• Although these drugs may be beneficial in the short-term, they are associated with a variety of side effects, including dependence, tolerance, and severe responses (Kripke). [Ebrahim Yasmina M. (2025); evidence level 4]
• Furthermore, long-term use of these drugs can result in rebound insomnia and withdrawal symptoms after termination (Lader). [Ebrahim Yasmina M. (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For saffron sleep latency meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Dormal Valérie (2025). The Effects of Combined Scutellaria and Saffron Supplementation on Mood Regulation in Participants with Mild-to-Moderate Depressive Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study. DOI: 10.3390/nu17050809. PMCID: PMC11901551. PMID: 40077679. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC11901551/
• Ebrahim Yasmina M. (2025). Integrative sleep management: from molecular pathways to conventional and herbal treatments. DOI: 10.1007/s00210-025-04183-y. PMCID: PMC12511158. PMID: 40338321. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511158/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.